Abstract:A series of 1H‐benzimidazole‐4‐carboxamide PARP‐1 inhibitors using different saturated nitrogen‐containing heterocycles as linker groups was designed synthesized and evaluated its anti‐proliferation activities of MDA‐MB‐436 cell to obtain the preferred structures of linker group and terminal group in the AD site. PARP‐1 inhibitors have been successfully applied in the clinical treatment of various cancer. Side effects and drug resistant cases were reported, and more effective PARP‐1 inhibitors were required. However, studies on the AD site of PARP‐1 inhibitors are currently incomplete. Therefore, to synthesize more potential candidate PARP‐1 inhibitors and disclose some AD site SAR of the PARP‐1 inhibitors, herein, a series of 2‐phenyl‐benzimidazole‐4‐carboxamide derivatives using different saturated nitrogen‐contained heterocycles as linker group (6a‐6t) have been designed, synthesized and evaluated PARP‐1 inhibitory activity and proliferation inhibitory against BRCA‐1 mutant MDA‐MB‐436 cell line in vitro. The results showed 6b (IC50 = 8.65 nM) exhibited the most PARP‐1 enzyme inhibitory activity comparable with Veliparib (IC50 = 15.54 nM) and Olaparib (IC50 =2.77 nM); 6m exhibited the strongest MDA‐MB‐436 cell anti‐proliferation activity (IC50=25.36±6.06 μM) comparable with Olaparib (IC50 = 23.89±3.81 μM). The compounds 6b, 6r, and 6m could be potential candidates for effective PARP‐1 inhibitors and valuable for further optimization. The analysis of activity data also showed that the holistically anti‐proliferation activity of the 1,4‐diazepane group was about~2 fold than that of the piperazine group. Meanwhile, the terminal 3‐methyl‐furanyl group exhibited the most robust PARP‐1 inhibitory and anti‐proliferation activity. It's hoped that the results could benefitable for further optimization of PARP‐1 inhibitors. Furthermore, we note that some compounds (6d,6g,6n,6p,6s) showed poor PARP‐1 inhibitory (>500 nM) but relatively good anti‐proliferation activity, which indicates the proliferation inhibitory mechanism against MDA‐MB‐436 cell line was worth investigating in‐depth.

Identification of Novel PARP-1 Inhibitors: Drug Design, Synthesis and Biological Evaluation.

Synthesis and in Vitro Biological Evaluation of 3-Ethyl-1,5-naphthyridin-2(1h)-one Derivatives As Potent PARP-1 Selective Inhibitors and PARP-1 DNA Trappers

Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage As Novel PARP1 Inhibitors

Novel 4,5-dihydrospiro[benzo[c]azepine-1,1′-cyclohexan]-3(2H)-one derivatives as PARP-1 inhibitors: Design, synthesis and biological evaluation

Design, Synthesis, Biological Evaluation and Molecular Docking Study of Novel Urea-Based Benzamide Derivatives As Potent Poly(adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Design, Synthesis, and Evaluation of 1H‐benzo[d]imidazole‐4‐carboxamide PARP‐1 Inhibitors Using Different Saturated Nitrogen‐Contained Heterocycle as linker Group

Design, Synthesis and Biological Evaluation of Novel 5-Fluoro-1h-benzimidazole-4-carboxamide Derivatives As Potent PARP-1 Inhibitors.

Discovery, Mechanism and Metabolism Studies of 2,3-Difluorophenyl-linker-containing PARP1 Inhibitors with Enhanced in Vivo Efficacy for Cancer Therapy

Design, Synthesis and Biological Evaluation of Novel Molecules As Potent PARP-1 Inhibitors.

Design, Synthesis and Bioevaluation of 1H-Indole4-carboxamide Derivatives As Potent Poly(Adp-Ribose) Polymerase-1 Inhibitors

Design, Synthesis and Activity Evaluation of New Phthalazinone PARP Inhibitors.

Discovery of Novel Benzamide Derivatives Bearing Benzamidophenyl and Phenylacetamidophenyl Scaffolds As Potential Antitumor Agents Via Targeting PARP-1.

Design, synthesis, and bioactivity study on Lissodendrins B derivatives as PARP1 inhibitor

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase

Design and Synthesis of Benzo-Spirocyclic Derivatives as Potent PARP-1 Inhibitors

Carbamoylation at C-8 position of natural 3-arylcoumarin scaffold for the discovery of novel PARP-1 inhibitors with potent anticancer activity

Design, Synthesis and Evaluation of Phthalazinone Thiohydantoin-Based Derivative As Potent PARP-1 Inhibitors.

Discovery of Potent 2,4-Difluoro-linker Poly(adp-Ribose) Polymerase 1 Inhibitors with Enhanced Water Solubility and in Vivo Anticancer Efficacy

Design and Synthesis of Novel Phthalazinone Derivatives As Potent Poly(adp-Ribose)polymerase 1 Inhibitors.

Discovery and SAR Study of 2-(1-propylpiperidin-4-yl)-3h-imidazo[4,5-c]pyridine-7-carboxamide: A Potent Inhibitor of Poly(adp-Ribose) Polymerase-1 (PARP-1) for the Treatment of Cancer.